A phase I clinical trial (NCT02713984) conducted by Southwest Hospital in China is currently evaluating the safety and efficacy of HER2-targeting CAR-T cells in patients with HER2-positive advanced solid tumors, including esophageal cancer and gastric cancer (9). Here, ERBB2 is linked to esophageal cancer.